Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers
Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers
复制标题
DOI：
10.21873/invivo.12980
复制
发表时间：
2022
期刊：
影响因子：
2.3
通讯作者：
A. Matsuoka;S. Tate;K. Nishikimi;M. Iwamoto;S. Otsuka;M. Shozu
中科院分区：
文献类型：
--
作者：
A. Matsuoka;S. Tate;K. Nishikimi;M. Iwamoto;S. Otsuka;M. Shozu
摘要背景/目的：2014年国际妇产科联合会（FIGO）分类根据转移性淋巴结的最大尺寸对IIIA 1期卵巢癌、输卵管癌和腹膜癌患者进行了细分，但没有支持性证据。本研究旨在评估这种细分的有效性。患者和方法：在2009年至2020年的卵巢癌、输卵管癌或腹膜癌患者中进行了一项回顾性单机构队列研究。我们比较了诊断为IIIA 1（i）（最大尺寸转移≤10 mm）和IIIA 1（ii）（最大尺寸转移>10 mm）的患者的结局。结果：在895例患者中，46例（5.1%）被分类为IIIA 1期，20例为IIIA 1（i）期，26例为IIIA 1（ii）期。在IIIA 1（ii）期，浆液性癌的病例数明显多于IIIA 1（i）期（p<0.001），阳性淋巴结数目和淋巴结比率明显高于IIIA 1（i）期（p=0.001，p=0.002）。IIIA 1（i）期癌症患者的5年无进展生存率为68.7%，IIIA 1（ii）期患者为58.1%（p=0.58）。IIIA 1（i）期癌症患者的5年总生存率为83.1%，IIIA 1（ii）期患者为80.2%（p=0.44）。在其他患者特征和病理结果中，IIIA 1期癌症患者没有预后因素。结论：在这项回顾性队列研究中，FIGO IIIA 1期癌症的进一步分类与患者结局无关。
Abstract Background/Aim: The 2014 International Federation of Gynecology and Obstetrics (FIGO) classification subdivides patients with stage IIIA1 ovarian, fallopian tube, and peritoneal cancers by the greatest dimension of metastatic lymph node without supporting evidence. This study aimed to assess the validity of this subdivision. Patients and Methods: A retrospective single-institution cohort study was performed in patients with ovarian, fallopian tube, or peritoneal cancer from 2009 to 2020. We compared outcomes between patients diagnosed with IIIA1(i) (metastasis ≤10 mm in the greatest dimension) and IIIA1(ii) (metastasis >10 mm in the greatest dimension). Results: Of the 895 patients, 46 (5.1%) were classified as stage IIIA1, 20 as IIIA1(i), and 26 as IIIA1(ii). In stage IIIA1(ii), there were significantly more cases of serous carcinoma (p<0.001), and the number of positive nodes and lymph node ratio were significantly higher than those in stage IIIA1(i) (p=0.001, p=0.002). Five-year progression-free survival was 68.7% in patients with stage IIIA1(i) cancer and 58.1% in those with stage IIIA1(ii) (p=0.58). Five-year overall survival was 83.1% in patients with stage IIIA1(i) cancer and 80.2% in those with stage IIIA1(ii) (p=0.44). Among other patient characteristics and pathologic findings, there were no prognostic factors for patients with stage IIIA1 cancer. Conclusion: In this retrospective cohort study, further classification of FIGO stage IIIA1 cancer was not significantly associated with patient outcomes.